Literature DB >> 11684080

Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats.

S Takeshita1, H Tomiyama, N Yokoyama, Y Kawamura, T Furukawa, Y Ishigai, T Shibano, T Isshiki, T Sato.   

Abstract

OBJECTIVES: Natural angiogenesis has been shown to be impaired in spontaneously hypertensive rats (SHR). The purpose of this study was to determine whether pathological angiogenesis in the setting of tissue ischemia is also impaired in SHR, and to what extent it is modified by angiotensin-converting enzyme (ACE) inhibition.
METHODS: Ischemia was induced in the hindlimb of SHR by excision of the femoral artery, after which the animals were randomly assigned to receive low-dose perindopril (sub-antihypertensive, 0.2 mg/kg/day), high-dose perindopril (antihypertensive, 2.0 mg/kg/day), or vehicle for 3 weeks. Wistar-Kyoto rats (WKY) with femoral artery excision served as a control group.
RESULTS: Tissue ACE activity in SHR was significantly increased compared to WKY (49.4+/-6.2 vs. 34.0+/-14.2 IU/mg, P<0.01). Administration of perindopril significantly reduced ACE activity in SHR (low dose: 12.4+/-2.3; high dose: 11.0+/-2.1 IU/mg, P<0.005). Angiogenesis of the ischemic limb muscles was significantly impaired at 4 weeks in SHR versus WKY as indicated by the lower capillary density in the former (364.5+/-43.0 vs. 463.8+/-63.0/mm(2), P<0.05) as well as the reduced hindlimb perfusion assessed by laser Doppler imaging (0.86+/-0.08 vs. 1.03+/-0.09, P<0.05). Administration of perindopril significantly augmented both the capillary density (low dose: 494.3+/-69.8; high dose: 543.9+/-76.9/mm(2), P<0.005) and the limb perfusion (low dose: 1.06+/-0.15; high dose: 1.05+/-0.12, P<0.05) of the ischemic limb in SHR.
CONCLUSIONS: These findings indicate that pathological angiogenesis in the setting of tissue ischemia is impaired in SHR compared with WKY, and that this impairment can be reversed by ACE inhibition. The angiogenic properties of an ACE inhibitor may benefit patients with essential hypertension presenting with lower limb vascular insufficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684080     DOI: 10.1016/s0008-6363(01)00372-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  12 in total

Review 1.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

Authors:  G Onder; C Della Vedova; F Landi
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

2.  Angiogenesis in mesenteric microvascular networks from spontaneously hypertensive versus normotensive rats.

Authors:  Ming Yang; Mario Aragon; Walter L Murfee
Journal:  Microcirculation       Date:  2011-10       Impact factor: 2.628

3.  Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin.

Authors:  S Zacharieva; I Atanassova; M Orbetzova; G Kirilov; E Nachev; K Kalinov; R Shigarminova
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

4.  Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.

Authors:  Annelise Letourneur; Simon Roussel; Myriam Bernaudin; Fabien Fillesoye; Jérôme Toutain; Eric T MacKenzie; Edwige Petit; Omar Touzani; Samuel Valable
Journal:  Hypertens Res       Date:  2015-06-18       Impact factor: 3.872

5.  Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.

Authors:  Kimiyasu Egami; Toyoaki Murohara; Toshifumi Shimada; Ken-Ichiro Sasaki; Satoshi Shintani; Takeshi Sugaya; Masahiro Ishii; Teiji Akagi; Hisao Ikeda; Toyojiro Matsuishi; Tsutomu Imaizumi
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 6.  The macrocirculation and microcirculation of hypertension.

Authors:  François Feihl; Lucas Liaudet; Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

7.  Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Authors:  Zachary S Morris; Sandeep Saha; William J Magnuson; Brett A Morris; Jenna F Borkenhagen; Alisa Ching; Gayle Hirose; Vanesa McMurry; David M Francis; Paul M Harari; Rick Chappell; Stuart Tsuji; Mark A Ritter
Journal:  Cancer       Date:  2016-05-20       Impact factor: 6.860

8.  Rescue of hypertension-related impairment of angiogenesis by therapeutic ultrasound.

Authors:  Zhao-Yang Lu; Rui-Lin Li; Hong-Sheng Zhou; Jing-Juan Huang; Jia Qi; Zhi-Xiao Su; Lan Zhang; Yue Li; Yi-Qin Shi; Chang-Ning Hao; Jun-Li Duan
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

9.  Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function.

Authors:  Jian-guang Yu; En-hui Zhang; Ai-jun Liu; Jian-guo Liu; Guo-jun Cai; Ding-feng Su
Journal:  Acta Pharmacol Sin       Date:  2013-11-18       Impact factor: 6.150

Review 10.  Nitric oxide signaling during myocardial angiogenesis.

Authors:  Takahisa Kondo; Koichi Kobayashi; Toyoaki Murohara
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.